Considerations when choosing oral chemotherapy: Identifying and responding to patient need

European Journal of Cancer Care

Volumn 19, Issue SUPPL. 1, 2010, Pages 5-11

  Irshad, S ^a   Maisey, N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954802840     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2010.01199.x     Document Type: Article

References (40)

1. Bajetta E, Di bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004, 100:279-287.
2. Borner MM, Schoffski P, De Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, Van Der Born K, Wanders J, De Boer RF, Martin C, Fumoleau P. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. European Journal of Cancer 2002, 38:349-358.
3. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, SalettI P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of Oncology 2005, 16:282-288.
4. Cassidy J, Twelves C, van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, Mckendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 2002, 13:566-575.
5. Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustovà I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. British Journal of Cancer 2006, 94:1122-1129.
6. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:2006-2012.
7. Cassidy J, Bridgewater J, Maisey N, Raouf S. Oral Chemotherapy Practical Guidance 2009 2009, Roche Ltd, London, England, UK
8. Darba J, Restovic G, Ramirez De Arellano A. Economic assessment of capecitabine/cisplatin versus 5-FU/cisplatin regimens in treatment of advanced gastric cancer in Spain. Presented at the 33rd congress of the European Society for Medical Oncology 2008, Stockholm, Sweden, September 12-16, 2008
9. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology 1997, 15:808-815.
10. Decision Resources Survey. Oral chemotherapeutic agents: key success factors and reimbursement issues. 2005, Decision Resources Inc, A survey of US Oncologists and HMO pharmacy directors
11. Demario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. Journal of Clinical Oncology 1998, 16:2557-2567.
12. Di Costanzo F, Sobrero A, Twelves C, Douillard J, Giuliani G, Patel K, Garrison L, Cassidy J. Italian economic evaluation of capecitabine vs. bolus 5-FU/LV as adjuvant chemotherapy for patients with Dukes' C colon cancer. Annals of Oncology 2006, 17:63. suppl 6, Abstr 130
13. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clinical Pharmacology and Therapeutics 1997, 62:41-49.
14. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2004, 22:23-30.
15. Harrold K. Effective management of adverse effects while on oral chemotherapy: implications for nursing practice. European Journal of Cancer Care 2010, 19(Suppl. 1):12-20.
16. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Journal of Clinical Oncology 2001, 19:2282-2292.
17. James R, Blanco C, Farina C. Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer. European Journal of Cancer 2003, 1(5):S83. Suppl.
18. Jansman FG, Postma MJ, Van Hartskamp D, Willemse PH, Brouwers JR. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clinical Therapeutics 2004, 26:579-589.
19. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65:17-22.
20. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 1997, 15:110-115.
21. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. Journal of Clinical Oncology 1989, 7:425-432.
22. Mcleod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clinical Cancer Research 1999, 5:2669-2671.
23. Maliepaard M, Van Gastelen MA, Tohgo A, Hausheer FH, Van Waardenburg RC, De Jong LA, Pluim D, Beijnen JH, Schellens JH. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clinical Cancer Research 2001, 7:935-941.
24. Odani A, Hashimoto Y, Takayanagi K, Otsuki Y, Koue T, Takano M, Yasuhara M, Hattori H, Furusho K, Inui K. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biological & Pharmaceutical Bulletin 1996, 19:444-448.
25. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute 2002, 94:652-661.
26. Patt Y, Liebmann T, Diamandidis D, Eckhardt G, Javle M, Justice G, Keiser L, Lee F, Miller W, Lin E. Final efficacy and safety findings from a phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC). Annals of Oncology 2004, 16:282-288.
27. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Social Science & Medicine 1992, 35:1505-1509.
28. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. Journal of Clinical Oncology 1992, 10:896-903.
29. Poorter RL, Lauw FN, Bemelman WA, Bakker PJ, Taat CW, Veenhof CH. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. European Journal of Cancer 1996, 32A:2262-2266.
30. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. The New England Journal of Medicine 2000, 343:905-914.
31. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of Oncology 2003, 14:1735-1743.
32. Sharma S. Patient selection for oral chemotherapy. Oncology (Williston Park, N.Y.) 2001, 15:33-35.
33. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 2004, 22:229-237.
34. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer 2001, 37:597-604.
35. Twelves C, Sheithauer W, McKendrick J, Nowacki M, Seitz J, Van Hazel G, Wong A, Diaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-FU/LV in stage III colon cancer: Updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. American Society of Clinical Oncology, 2008 Gastronintestinal Cancers Symposium 2008, In, General Poster Session E. (Abstr 274), Orlando, FL, USA
36. van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, Mckendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology 2001, 19:4097-4106.
37. van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. British Journal of Cancer 2004, 90:1190-1197.
38. Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, Shulman LN, Connor M. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 2007, 334:407.
39. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS. NCCN task force report: oral chemotherapy. Journal of the National Comprehensive Cancer Network: JNCCN 2008, 6(3):S1-S14. Suppl.
40. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. Journal of Clinical Pharmacology 1997, 37:92-100.